JPH04243825A - Remedy for pigmentation - Google Patents
Remedy for pigmentationInfo
- Publication number
- JPH04243825A JPH04243825A JP3023770A JP2377091A JPH04243825A JP H04243825 A JPH04243825 A JP H04243825A JP 3023770 A JP3023770 A JP 3023770A JP 2377091 A JP2377091 A JP 2377091A JP H04243825 A JPH04243825 A JP H04243825A
- Authority
- JP
- Japan
- Prior art keywords
- pigmentation
- hyperpigmentation
- acid
- ascorbic acid
- tranexamic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000019612 pigmentation Effects 0.000 title abstract description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 11
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 11
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 8
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 8
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 208000000069 hyperpigmentation Diseases 0.000 claims description 11
- 230000003810 hyperpigmentation Effects 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 229940126701 oral medication Drugs 0.000 claims 1
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 description 8
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 229940086764 ascorbic acid 1000 mg Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
【０００１】0001
【産業上の利用分野】本発明は色素沈着症に対して優れ
た効果を有する内服型の色素沈着症治療剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an internally administered agent for treating hyperpigmentation which has excellent effects on hyperpigmentation.
【０００２】0002
【従来の技術】色素沈着症は、一般に、遺伝的素因、ホ
ルモンの異常、日光の紫外線刺激、光力学的物質等の皮
膚刺激、アレルギー性接触皮膚炎の悪化等により、皮膚
内にメラニンが異常沈着することによっておこるものと
考えられている。このような色素沈着症の治療法として
は、従来、ハイドロキノン、ビタミンＣ誘導体、コウジ
酸、トラネキサム酸等を含有する外用剤；ビタミンＣ、
Ｌ−システイン、グルタチオン、トラネキサム酸等を含
有する内服剤が提案され、そのうちのあるものは実際に
市場に提供されているが、ハイドロキノン製剤以外には
、短期間に充分な効果が認められるものはない。しかし
ながら、ハイドロキノン製剤は副作用が強いために、本
邦ではほとんど使用されていない。[Prior Art] Hyperpigmentation is generally caused by abnormal melanin in the skin due to genetic predisposition, hormonal abnormalities, ultraviolet stimulation from sunlight, skin irritation from photodynamic substances, exacerbation of allergic contact dermatitis, etc. It is thought that this is caused by deposition. Conventional treatments for such hyperpigmentation include topical preparations containing hydroquinone, vitamin C derivatives, kojic acid, tranexamic acid, etc.;
Oral preparations containing L-cysteine, glutathione, tranexamic acid, etc. have been proposed, and some of them are actually available on the market, but other than hydroquinone preparations, there are no drugs that have been shown to be sufficiently effective in a short period of time. do not have. However, hydroquinone preparations are rarely used in Japan because of their strong side effects.
【０００３】0003
【発明が解決しようとす課題】従って、本発明は、副作
用がなく安定性が高く、短期間の投与で充分な効果が期
待できる色素沈着症治療剤を提供することを目的とする
ものである。[Problems to be Solved by the Invention] Therefore, it is an object of the present invention to provide a therapeutic agent for hyperpigmentation that has no side effects, is highly stable, and can be expected to be sufficiently effective when administered for a short period of time. .
【０００４】0004
【課題を解決するための手段】斯かる実情において、本
発明者は鋭意研究を行った結果、単独の内服でもある程
度の治療効果が認められるトラネキサム酸に、単独では
あまり効果が認められないアスコルビン酸又はその塩を
配合することにより、色素沈着症の治療効果が相乗的に
増大し、短期間の投与で優れた効果が得られることを見
出し、本発明を完成した。[Means for Solving the Problem] Under these circumstances, the present inventor has conducted intensive research and found that tranexamic acid, which has some therapeutic effect even when taken alone, and ascorbic acid, which has little effect when taken alone. The present invention has been completed based on the discovery that the therapeutic effect of hyperpigmentation can be synergistically increased by incorporating a pigment or a salt thereof, and that excellent effects can be obtained with short-term administration.
【０００５】すなわち、本発明は、トラネキサム酸、及
びアスコルビン酸又はその塩を含有する内服薬形態の色
素沈着症治療剤を提供するものである。[0005] That is, the present invention provides a therapeutic agent for hyperpigmentation in the form of an internal medicine containing tranexamic acid and ascorbic acid or a salt thereof.
【０００６】本発明治療剤の一成分であるトラネキサム
酸は抗プラスミン剤として用いられているもので、ＬＤ
５０が５ｇ／ｋｇ以上（イヌの経口）と極めて毒性の低
いものである。また、アスコルビン酸もＬＤ５０が５ｇ
／ｋｇ以上（イヌの経口）の極めて毒性の低いものであ
る。アスコルビン酸の塩としては、ナトリウム塩、カル
シウム塩等が挙げられる。Tranexamic acid, which is one of the components of the therapeutic agent of the present invention, is used as an anti-plasmin agent and is effective against LD.
50 has an extremely low toxicity of 5 g/kg or more (orally for dogs). Also, ascorbic acid has an LD50 of 5g.
/kg or more (orally administered to dogs), which has extremely low toxicity. Salts of ascorbic acid include sodium salts, calcium salts, and the like.
【０００７】本発明の色素沈着症治療剤は、トラネキサ
ム酸、及びアスコルビン酸又はその塩が、共にそれぞれ
１日量として、５００ 〜１，５００ｍｇ、特に１，０
００ 〜１，５００ｍｇ になるように、１日に１〜数
回、特に３回に分けて投与するのが好ましい。The therapeutic agent for pigmentation of the present invention contains tranexamic acid and ascorbic acid or a salt thereof in a daily dose of 500 to 1,500 mg, particularly 1,0
It is preferable to administer 00 to 1,500 mg once to several times a day, particularly in 3 divided doses.
【０００８】本発明の色素沈着症治療剤は経口投与の形
態、例えば顆粒剤、細粒剤、散剤、カプセル剤、錠剤、
液剤等の種々の製剤とすることができる。これらの製剤
を製造するには、上記必須成分のほかに、かかる場合に
一般に使用されている助剤及び他の薬剤等を使用するこ
とができ、その製法は自体公知の方法によって行われる
。The therapeutic agent for hyperpigmentation of the present invention can be administered in the form of oral administration, such as granules, fine granules, powders, capsules, tablets, etc.
It can be made into various preparations such as liquid preparations. To manufacture these preparations, in addition to the above-mentioned essential ingredients, auxiliary agents and other drugs commonly used in such cases can be used, and the preparation is carried out by methods known per se.
【０００９】[0009]
【実施例】次に実施例を挙げて説明する。[Example] Next, an example will be given and explained.
【００１０】実施例１
アスコルビン酸
１０００ｍｇトラネキサム酸
１０００ｍｇ粉糖
２４
７５ｍｇ軽質無水ケイ酸
２５ｍｇ以上の成分から常法によって
顆粒剤を製造し、これを３包に分包し、１日分とした。Example 1 Ascorbic acid
1000mg tranexamic acid
1000mg powdered sugar
24
75mg light silicic anhydride
Granules were produced from 25 mg or more of the ingredients by a conventional method, and the granules were divided into three packages for one day's worth.
【００１１】試験例１
下記に示す３種の顆粒剤、すなわち実施例１で調製した
薬剤（Ａ）、トラネキサム酸単味剤（Ｂ）及びアスコル
ビン酸単味剤（Ｃ）を、色素沈着症の１種である肝斑患
者（全て女性）に１回１包、１日３回、２ケ月間経口投
与し、投与前後の色素沈着の程度を比較する単純比較臨
床試験を行った。〔１日量（３包）中〕薬剤
（Ａ） （
Ｂ） （Ｃ）
アスコルビン酸 １０００ｍｇ
− １０００ｍｇトラネキサム酸
１０００ｍｇ １５００ｍｇ−
粉糖
２４７５ｍｇ ２９７５ｍｇ ３４７５
ｍｇ
軽質無水ケイ酸 ２５ｍｇ
２５ｍｇ２５ｍｇそのときの、薬剤の投与
前後の症状変化は表１〔（Ａ）投与群〕、表２〔（Ｂ）
投与群〕及び表３〔（Ｃ）投与群〕のとおりであり、こ
れに基づいて評価した色素沈着症の改善度は表４に示す
とおりである。Test Example 1 The following three types of granules, namely the drug (A) prepared in Example 1, tranexamic acid monotherapy (B) and ascorbic acid monotherapy (C), were used to treat pigmentation disorders. A simple comparative clinical trial was conducted in which the drug was orally administered to patients with melasma, a type of melasma (all women), three times a day for two months, and the degree of pigmentation before and after administration was compared. [Daily dose (3 packages)] Drugs
(A) (
B) (C) Ascorbic acid 1000mg
- 1000mg tranexamic acid
1000mg 1500mg-
powdered sugar
2475mg 2975mg 3475
mg Light anhydrous silicic acid 25mg
Table 1 [(A) administration group] and Table 2 [(B)
Administration Group] and Table 3 [(C) Administration Group], and the degree of improvement in pigmentation that was evaluated based on this is as shown in Table 4.
【００１２】0012
【表１】[Table 1]
【００１３】[0013]
【表２】[Table 2]
【００１４】[0014]
【表３】[Table 3]
【００１５】[0015]
【表４】[Table 4]
【００１６】[0016]
【発明の効果】本発明の色素沈着症治療剤は副作用がな
く、経口投与によって、短期間に色素沈着症を有効に治
療することができる。EFFECTS OF THE INVENTION The agent for treating hyperpigmentation of the present invention has no side effects and can effectively treat hyperpigmentation within a short period of time by oral administration.
Claims (1)
又はその塩を含有する内服薬形態の色素沈着症治療剤。1. A therapeutic agent for hyperpigmentation in the form of an oral medication containing tranexamic acid and ascorbic acid or a salt thereof.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3023770A JPH04243825A (en) | 1991-01-25 | 1991-01-25 | Remedy for pigmentation |
| CA002086565A CA2086565A1 (en) | 1991-01-25 | 1992-12-31 | Pharmaceutical composition for treating pigmentation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3023770A JPH04243825A (en) | 1991-01-25 | 1991-01-25 | Remedy for pigmentation |
| CA002086565A CA2086565A1 (en) | 1991-01-25 | 1992-12-31 | Pharmaceutical composition for treating pigmentation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04243825A true JPH04243825A (en) | 1992-08-31 |
Family
ID=25675787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3023770A Pending JPH04243825A (en) | 1991-01-25 | 1991-01-25 | Remedy for pigmentation |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPH04243825A (en) |
| CA (1) | CA2086565A1 (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10101522A1 (en) * | 1997-07-08 | 2002-07-25 | Rath Matthias | Composition for treating collagenase-linked degenerative diseases, e.g. atherosclerosis, cancer and infections, comprises ascorbate and a fibrinolysis inhibitor |
| JP2004091473A (en) * | 2002-07-12 | 2004-03-25 | Tadayasu Takada | Therapeutic agent for improving chromatosis |
| WO2004060364A1 (en) | 2002-12-27 | 2004-07-22 | Daiichi Pharmaceutical Co., Ltd. | Skin lightening composition |
| US6974833B2 (en) | 2001-01-16 | 2005-12-13 | Matthias Rath | Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration |
| WO2006003965A1 (en) * | 2004-06-30 | 2006-01-12 | Daiichi Sankyo Healthcare Co., Ltd. | Skin-whitening compositions |
| JP2008508275A (en) * | 2004-07-30 | 2008-03-21 | ザノダイン ファーマシューティカルズ，インコーポレーテッド | Tranexamic acid preparation |
| WO2010016509A1 (en) | 2008-08-06 | 2010-02-11 | 第一三共ヘルスケア株式会社 | Stable pharmaceutical composition containing tranexamic acid and ascorbic acid |
| WO2010027010A1 (en) | 2008-09-05 | 2010-03-11 | 第一三共ヘルスケア株式会社 | Pharmaceutical solid preparation having active ingredients separated by boundary therein |
| WO2010029930A1 (en) | 2008-09-12 | 2010-03-18 | 第一三共ヘルスケア株式会社 | Stable pharmaceutical formulation with limited discoloration |
| US7947739B2 (en) | 2004-03-04 | 2011-05-24 | Ferring B.V. | Tranexamic acid formulations |
| US8022106B2 (en) | 2004-03-04 | 2011-09-20 | Ferring B.V. | Tranexamic acid formulations |
| US8273795B2 (en) | 2004-03-04 | 2012-09-25 | Ferring B.V. | Tranexamic acid formulations |
| US8957113B2 (en) | 2004-03-04 | 2015-02-17 | Ferring B.V. | Tranexamic acid formulations |
| US8968777B2 (en) | 2003-07-31 | 2015-03-03 | Ferring B.V. | Tranexamic acid formulations with reduced adverse effects |
-
1991
- 1991-01-25 JP JP3023770A patent/JPH04243825A/en active Pending
-
1992
- 1992-12-31 CA CA002086565A patent/CA2086565A1/en not_active Abandoned
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10101522B4 (en) * | 1997-07-08 | 2007-02-22 | Rath, Matthias, Dr. | New pharmaceutical use of a combination of ascorbate and at least one fibrinolytic inhibitor |
| DE10101522A1 (en) * | 1997-07-08 | 2002-07-25 | Rath Matthias | Composition for treating collagenase-linked degenerative diseases, e.g. atherosclerosis, cancer and infections, comprises ascorbate and a fibrinolysis inhibitor |
| US6974833B2 (en) | 2001-01-16 | 2005-12-13 | Matthias Rath | Synergistic compositions comprising ascobate and lysine for states related to extra cellular matrix degeneration |
| JP2004091473A (en) * | 2002-07-12 | 2004-03-25 | Tadayasu Takada | Therapeutic agent for improving chromatosis |
| JP4667875B2 (en) * | 2002-12-27 | 2011-04-13 | 第一三共ヘルスケア株式会社 | Whitening composition |
| JPWO2004060364A1 (en) * | 2002-12-27 | 2006-05-11 | 第一製薬株式会社 | Whitening composition |
| KR101107754B1 (en) * | 2002-12-27 | 2012-01-20 | 다이이찌 산쿄 헬스케어 가부시키가이샤 | Composition for preventing or treating pigmentations |
| WO2004060364A1 (en) | 2002-12-27 | 2004-07-22 | Daiichi Pharmaceutical Co., Ltd. | Skin lightening composition |
| US8968777B2 (en) | 2003-07-31 | 2015-03-03 | Ferring B.V. | Tranexamic acid formulations with reduced adverse effects |
| US7947739B2 (en) | 2004-03-04 | 2011-05-24 | Ferring B.V. | Tranexamic acid formulations |
| US8487005B2 (en) | 2004-03-04 | 2013-07-16 | Ferring B.V. | Tranexamic acid formulations |
| US9060939B2 (en) | 2004-03-04 | 2015-06-23 | Ferring B.V. | Tranexamic acid formulations |
| US8809394B2 (en) | 2004-03-04 | 2014-08-19 | Ferring B.V. | Tranexamic acid formulations |
| US8791160B2 (en) | 2004-03-04 | 2014-07-29 | Ferring B.V. | Tranexamic acid formulations |
| US8957113B2 (en) | 2004-03-04 | 2015-02-17 | Ferring B.V. | Tranexamic acid formulations |
| US8273795B2 (en) | 2004-03-04 | 2012-09-25 | Ferring B.V. | Tranexamic acid formulations |
| US8022106B2 (en) | 2004-03-04 | 2011-09-20 | Ferring B.V. | Tranexamic acid formulations |
| WO2006003965A1 (en) * | 2004-06-30 | 2006-01-12 | Daiichi Sankyo Healthcare Co., Ltd. | Skin-whitening compositions |
| JP2011168596A (en) * | 2004-07-30 | 2011-09-01 | Ferring Bv | Tranexamic acid formulation |
| JP2008508275A (en) * | 2004-07-30 | 2008-03-21 | ザノダイン ファーマシューティカルズ，インコーポレーテッド | Tranexamic acid preparation |
| JP2014193878A (en) * | 2004-07-30 | 2014-10-09 | Ferring Bv | Tranexamic acid formulations |
| JP2008508276A (en) * | 2004-07-30 | 2008-03-21 | ザノダイン ファーマシューティカルズ，インコーポレーテッド | Tranexamic acid preparation |
| WO2010016509A1 (en) | 2008-08-06 | 2010-02-11 | 第一三共ヘルスケア株式会社 | Stable pharmaceutical composition containing tranexamic acid and ascorbic acid |
| WO2010027010A1 (en) | 2008-09-05 | 2010-03-11 | 第一三共ヘルスケア株式会社 | Pharmaceutical solid preparation having active ingredients separated by boundary therein |
| KR20110057145A (en) | 2008-09-05 | 2011-05-31 | 다이이찌 산쿄 헬스케어 가부시키가이샤 | Pharmaceutical solid preparation having active ingredients separated by boundary therein |
| JP5498387B2 (en) * | 2008-09-12 | 2014-05-21 | 第一三共ヘルスケア株式会社 | Stable pharmaceutical formulation with suppressed discoloration |
| WO2010029930A1 (en) | 2008-09-12 | 2010-03-18 | 第一三共ヘルスケア株式会社 | Stable pharmaceutical formulation with limited discoloration |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2086565A1 (en) | 1994-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8349359B2 (en) | Liposomal formulation for oral administration of glutathione (reduced) | |
| AU765749B2 (en) | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein | |
| US6524623B1 (en) | Therapeutic compositions and methods of use thereof | |
| JPH0222229A (en) | Combination preparation used in treatment of disease or injury of nerve cell and nerve fiber | |
| EP1817006B1 (en) | Liposomal formulation for oral administration of glutathione (reduced) | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| JPH04243825A (en) | Remedy for pigmentation | |
| CA2570474A1 (en) | A combination composition comprising paracetamol and ibuprofen | |
| JPS62500789A (en) | Nasal composition containing vitamin B↓1↓2 | |
| CA2814057A1 (en) | Intravenous composition comprising paracetamol and ibuprofen | |
| KR20110074513A (en) | Topical treatment of skin infection | |
| RU95101385A (en) | Products containing g-csf and tnf-binding protein | |
| AU2008203101A1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
| KR910005858A (en) | Fatty acid therapy | |
| JP4786127B2 (en) | Antipigmentation treatment | |
| JPS5938203B2 (en) | A therapeutic agent for cerebral circulation disorders whose main ingredient is coenzyme Q. | |
| US6979468B1 (en) | Oral composition and method for the treatment of inflammatory cutaneous disorders | |
| JP2022507646A (en) | Uses of braiaconitine A | |
| Binnick | Pityriasis rubra pilaris responding to aminonicotinamide | |
| JPH11510824A (en) | Cosmetic method for treatment and prevention of signs of skin aging | |
| AU616755B2 (en) | Topically applied gold organic complex | |
| EP1437140B1 (en) | Oral pharmaceutical formulation containing active carbon and use of the same | |
| US20050158404A1 (en) | Composition and method for treatment of acne | |
| EVERETT et al. | Intradermal Administration of Chloroquine: For Discoid Lupus Erythematosus and Lichen Sclerosus et Atrophicus | |
| EP0402208B1 (en) | Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 19940719 |